DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/8zhdx6/chinese_markets) has announced the addition of the "Chinese Markets for Ovarian Cancer Treatment Drugs" report to their offering.
China's demand for ovarian cancer treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021 are presented. Major producers in China are profiled.
Key Topics Covered:
II. BUSINESS ENVIRONMENT
III. OVARIAN CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
IV. OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND
V. OVARIAN CANCER TREATMENT DRUGS MARKET OUTLOOK
VI. MARKET ENTRY CHANNELS
VII. OVARIAN CANCER TREATMENT DRUGS PRODUCER DIRECTORY
LIST OF TABLES
LIST OF CHARTS
Beijing SL Pharmaceutical Co., Ltd
Yangtze River Pharmaceutical Group
Hangzhou Aoyipollen Pharmaceutical Co., Ltd.
Zhuhai Union Pharmaceutical Co., Ltd
Shandong Qilu Pharmaceutical Co., Ltd
Chengdu Minyi Pharmaceutical Co., Ltd
Henan Jiaozuo KL Pharmaceutical Co., Ltd
Changzhou Siyao Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/8zhdx6/chinese_markets
Source: Research and Markets